275 related articles for article (PubMed ID: 21502632)
1. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.
Wiederhold NP; Najvar LK; Bocanegra RA; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2011 Jul; 55(7):3254-60. PubMed ID: 21502632
[TBL] [Abstract][Full Text] [Related]
2. The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.
Wiederhold NP; Najvar LK; Fothergill AW; McCarthy DI; Bocanegra R; Olivo M; Kirkpatrick WR; Everson MP; Duncanson FP; Patterson TF
Antimicrob Agents Chemother; 2015 Jan; 59(1):690-2. PubMed ID: 25331706
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.
Brzankalski GE; Najvar LK; Wiederhold NP; Bocanegra R; Fothergill AW; Rinaldi MG; Pattterson TF; Graybill JR
J Antimicrob Chemother; 2008 Nov; 62(5):1094-100. PubMed ID: 18658194
[TBL] [Abstract][Full Text] [Related]
4. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
5. The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.
Wiederhold NP; Najvar LK; Fothergill AW; Bocanegra R; Olivo M; McCarthy DI; Kirkpatrick WR; Fukuda Y; Mitsuyama J; Patterson TF
Antimicrob Agents Chemother; 2015 Feb; 59(2):1341-3. PubMed ID: 25451054
[TBL] [Abstract][Full Text] [Related]
6. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungin.
Toutounji M; Tokajian S; Khalaf RA
Fungal Genet Biol; 2019 Jun; 127():12-22. PubMed ID: 30794951
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
Arendrup MC; Garcia-Effron G; Buzina W; Mortensen KL; Reiter N; Lundin C; Jensen HE; Lass-Flörl C; Perlin DS; Bruun B
Antimicrob Agents Chemother; 2009 Mar; 53(3):1185-93. PubMed ID: 19104024
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
[TBL] [Abstract][Full Text] [Related]
11. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
[TBL] [Abstract][Full Text] [Related]
12. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.
Dimopoulou D; Hamilos G; Tzardi M; Lewis RE; Samonis G; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(1):229-36. PubMed ID: 24145540
[TBL] [Abstract][Full Text] [Related]
13. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.
Lee KK; Maccallum DM; Jacobsen MD; Walker LA; Odds FC; Gow NA; Munro CA
Antimicrob Agents Chemother; 2012 Jan; 56(1):208-17. PubMed ID: 21986821
[TBL] [Abstract][Full Text] [Related]
14. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
[No Abstract] [Full Text] [Related]
15. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation studies with caspofungin against Candida glabrata.
Domán M; Kovács R; Perlin DS; Kardos G; Gesztelyi R; Juhász B; Bozó A; Majoros L
J Med Microbiol; 2015 Sep; 64(9):998-1007. PubMed ID: 26296340
[TBL] [Abstract][Full Text] [Related]
17. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
18. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.
Wiederhold NP; Najvar LK; Jaramillo R; Olivo M; Pizzini J; Catano G; Patterson TF
J Antimicrob Chemother; 2018 Feb; 73(2):448-451. PubMed ID: 29177447
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
20. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
